Quarterly ResultAug 13, 2026, 05:01 PM
BIO-key Q2 Revenue +13% to $1.9M; Net Loss Trimmed 51% to $(577K)
AI Summary
BIO-key International reported strong financial improvements for Q2 and 1H 2026, with Q2 revenues increasing 13% to $1.9M and net loss trimmed by 51% to $(577K). The company's gross margin improved significantly to 87%. BIO-key also raised $2.5M through warrant exercises, boosting its cash position to over $4.5M, and announced new partnerships and customer wins in the EMEA region and the U.S. The company anticipates continued revenue growth and profitability in the second half of 2026, supported by a delayed hardware order and a robust pipeline.
Key Highlights
- Q2'26 revenues increased 13% to $1.9M, driven by 53% growth in license fee revenue.
- Q2'26 net loss was trimmed by 51% to $(577K) compared to $(1.2M) in Q2'25.
- Q2'26 gross margin improved to 87% from 73% in Q2'25, reflecting higher-margin license fees.
- 1H'26 revenues grew 23% and net loss improved by 59% compared to 1H'25.
- Raised $2.5M from warrant exercises, increasing current cash position to over $4.5M.
- Partnered with Maktabi Tech in Saudi Arabia and secured deals in Portugal and Jordan.
- Completed a 1-for-10 reverse stock split and regained Nasdaq listing compliance in Q2'26.
Price Impact
More from BKYI